abstract: UNASSIGNED: 8034 Background: Dying in a hospital, particularly on an intensive care unit (ICU), can be traumatic for @entity1 and families. Palliative care services (PCS) and a palliative care unit (PCU) improve severe physical and psychosocial symptoms, but they are not available in the majority of @entity5 centers and tertiary hospitals. The purpose of this paper is to review the impact of a PCS/PCU on overall hospital mortality at the University of Texas M.D. Anderson @entity5 Center. METHODS: We reviewed inpatient hospital @entity204 (including number of @entity204 , hospital location of @entity204 , and medical service), hospital discharges, and medical service information from the years 1999-2003. We determined the number of @entity1 who accessed PCS before @entity204 (via consults or PCU admission). The Cochran-Armitage Trend Test was used to test for trends over time. RESULTS: See table below. CONCLUSIONS: Establishment of PCS and PCU resulted in no significant increase in hospital mortality or length of stay. Coordinated efforts between PCS, ICU, and an ethics consult service resulted in a decrease in ICU @entity204 . By 2003, PCS had increased significantly. [Figure: see text] No significant financial relationships to disclose.

title: The impact of a palliative care service on overall hospital mortality in a comprehensive XXXX center.

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: The effects of local @entity5 @entity221 on regional lymph node @entity3 are inconclusive. We studied the effects of @entity221 on the incidence of popliteal, femoral, and abdominal lymph node @entity3 in C57BL/6 @entity19 with primary @entity6844 ( @entity48401 variant) growing subcutaneously in the left foot. @entity5 were heated to 42.3, 43.5, and 44.2 degrees C for 90 minutes either 7 days after inoculation of 5 X 10(4) viable cells (microscopic @entity5 = mic) or when the @entity5 were approximately 3 mm in diameter (macroscopic @entity5 = mac). Femoral lymph node @entity3 occurred in 0/21 control animals and in 8/22 (36%), 11/19 (58%), and 11/17 (65%) animals whose @entity5 were heated to 42.3, 43.5, and 44.2 degrees C, respectively. For all three treatments, the increase in @entity3 as compared to controls was statistically significant (p less than 0.004, Fisher's exact test). The incidence of abdominal lymph node @entity3 was slightly higher in the treated groups than controls. Twenty of 21 (95%) control @entity19 developed popliteal lymph node @entity3 and @entity221 -induced increases could not be demonstrated. Fifteen of 21 control @entity19 killed 3 weeks after amputation of @entity5 -containing leg had pulmonary @entity3 with an average of 6 +/- 4 (standard deviation) lesions per affected @entity19 . Pulmonary @entity3 occurred in 22/22 (100%), 17/19 (89%), and 13/17 (76%) of @entity19 whose @entity5 were heated to 42.3, 43.5, and 44.2 degrees C, respectively. The numbers of @entity3 for affected @entity19 were significantly increased compared to controls for @entity5 heated to 43.5 and 44.2 degrees C (28 +/- 43, 43 +/- 52, 119 +/- 121, p greater than 0.02, p less than 0.006, p less than 0.002, for two sample T-test). While 0/8 mic @entity5 were cured 5/9 mac @entity5 heated to 44.2 degrees C disappeared (p less than 0.03, Fisher's exact test) and there was a growth delay in the remaining @entity19 . @entity5 , heated to 43.5 degrees C, had an accelerated onset of growth while mac @entity5 heated to this temperature had a slight growth delay. Growth of both mic and mac @entity5 heated to 42.3 degrees C was similar to controls. These results show that therapeutic and subtherapeutic local @entity221 increases @entity3 to regional lymph nodes and to lungs even when primary @entity5 growth rate is partially or totally controlled.

title: Regional lymph node and pulmonary XXXX after local @entity221 of melanomas in C57BL/6 @entity19 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'primary tumors', 'Mic tumors', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: BACKGROUND: We previously classified camptocormia of @entity191 ( @entity191 ) into upper and lower types based on the inflection point, and reported improvement of @entity3518 after @entity3303 injection into the external oblique. However, the exact pathophysiology of this phenomenon remains obscure. METHODS: Surface electromyography (sEMG) was recorded in 11 @entity191 @entity1 with @entity3518 , 11 @entity191 @entity1 with @entity3518 , and 10 age-matched @entity191 @entity1 without @entity85 . Electrodes were positioned above the external oblique, hip flexors and paraspinal muscles at Th11 level bilaterally. Recording commenced with the @entity1 in supine position on a tilt table, and continued when the table was tilted up to vertical position. @entity3303 was injected into the external oblique in @entity1 with @entity3518 and the psoas major in @entity1 with @entity3518 . RESULTS: All @entity1 with upper and @entity3518 developed the corresponding camptocormic posture during tilt up. The onset of camptocormic posture was preceded by the appearance of sEMG activity in the external oblique in 10 out of 11 @entity1 with @entity3518 , but less frequently in @entity1 with @entity3518 and the controls. Hip flexors sEMG activity was recorded in almost all @entity1 . Posture was improved in 8 out of 9 @entity1 with @entity3518 , and 9 out of 11 @entity1 with @entity3518 following injections of @entity3303 . CONCLUSIONS: The results suggest the external oblique is involved, at least in part, in the development of @entity3518 . Although EMG findings cannot differentiate pathogenicity, the psoas major is probably involved in @entity3518 .

title: Mechanism of camptocormia in XXXX analyzed by tilt table-EMG recording.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

entities_list: @entity3518 :: ('MESH:C537968', 'Disease') :: ['upper camptocormia', 'lower camptocormia']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine', 'Lidocaine']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['postural deformity']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: PURPOSE: The goal of this study was to assess the effect of @entity8142 agonists ( @entity6757 RAs) on lipid profiles in @entity1 with @entity164 2 @entity6 . METHODS: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controlled trials with available data were selected if they compared @entity6757 RAs with placebo and traditional antidiabetic drugs with a duration >= 8 weeks. The weighted mean difference for changes in lipid profiles was estimated by using the random effects model, and a network meta-analysis was performed to supplement direct comparisons. FINDINGS: Thirty-five trials with 13 treatments were included in the analysis. @entity6757 RAs decreased HDL-C with a range of -0.06 mmol/L (95% CI, -0.11 to -0.01) to -0.13 mmol/L (95% CI, -0.17 to -0.10) compared with @entity12721 , whereas @entity12721 were associated with a significant increase in HDL-C compared with placebo (0.09 mmol/L [95% CI, 0.06 to 0.12]). A significant reduction in LDL-C was detected for all @entity6757 RAs versus placebo (range, -0.08 to -0.16 mmol/L), insulin (range, -0.10 to -0.19 mmol/L), and @entity12721 (range, -0.16 to -0.24 mmol/L). Exenatide, liraglutide 1.8 mg once daily, and @entity22259 decreased total @entity165 with a range of -0.16 mmol/L (95% CI, -0.26 to -0.06) to -0.27 mmol/L (95% CI, -0.41 to -0.12) versus placebo and @entity12721 (range, -0.26 to -0.37 mmol/L). The decreased effect was more evident in exenatide long-acting release and liraglutide 1.8 mg once daily. A significant reduction in @entity412 levels was observed with liraglutide 1.8 mg once daily (-0.30 mmol/L [95% CI, -0.49 to -0.11]) and @entity22259 20 mg once weekly (-0.17 mmol/L [95% CI, -0.31 to -0.01]) versus placebo. IMPLICATIONS: @entity6757 RAs were associated with modest reductions in LDL-C, total @entity165 , and @entity1674 but no significant improvement in HDL-C. Further evidence is needed to determine if improvements in lipid profiles might translate into reductions in cardiovascular outcomes.

title: Effect of XXXX Agonists on Lipid Profiles Among Type 2 @entity6 : A Systematic Review and Network Meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity22259 :: ('MESH:C541736', 'Chemical') :: ['taspoglutide']

entities_list: @entity12721 :: ('MESH:D045162', 'Chemical') :: ['thiazolidinediones']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity8142 :: ('2740', 'Gene') :: ['glucagon-like peptide-1 receptor']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity8142 :: (2740,Gene) :: ['Glucagon-like Peptide-1 Receptor']


abstract: @entity8438 ( @entity8438 ) is a newly identified @entity358 associated with a variety of molecular defects affecting surfactant synthesis and secretion in alveolar type II cells. The authors present ultrastructural findings of abnormal lamellar bodies in lung biopsies from 4 @entity1 with @entity8438 . All were term @entity1 presenting shortly after birth with severe @entity1576 that was unresponsive to conventional therapy and all died within the first month of life. Lung biopsies were performed between 8 and 25 days of age. Biochemical and molecular studies in 2 unrelated male @entity1 identified @entity25097 deficiency, one case with 121 ins 2 mutation and the second with a @entity59197 mutation. Light microscopy in both cases showed features of @entity5970 . Ultrastructurally, alveolar type II cells lacked mature lamellar bodies, and their cytoplasm contained numerous pleomorphic inclusions with membranous and vesicular structures not seen in normal type II cells. The other 2 @entity1 were a pair of siblings in whom molecular studies identified mutations in @entity8437 transporter gene. Light microscopy showed features of @entity3981 and @entity3130 . TEM studies revealed absence of mature lamellar bodies in type II cells and instead showed a mixture of cytoplasmic electron-dense inclusions with concentric membranes and distinctive electron dense aggregates. The ultrastructural changes in alveolar type II cells correlated well with specific gene defect. In @entity25097 deficiency, the absence of mature lamellar bodies is consistent with the postulated role for this protein in the formation of lamellar bodies. The lack of mature lamellar bodies in the @entity8437 gene mutations is due to the dysfunction of this endogenous lipid transporter that targets surfactant lipid moieties to the lamellar bodies. The findings demonstrate the importance of TEM studies of lung biopsies from @entity1 with @entity8438 as it is a critical adjunct in the diagnosis of @entity358 and in defining the underlying cellular defects.

title: Ultrastructure of lamellar bodies in XXXX .

entities_list: @entity3130 :: ('MESH:C562470', 'Disease') :: ['desquamative interstitial pneumonitis']

entities_list: @entity3981 :: ('MESH:D018267', 'Disease') :: ['acinar dysplasia']

entities_list: @entity8438 :: ('MESH:C580477', 'Disease') :: ['CSD', 'Congenital surfactant deficiency']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['neonatal lung disease', 'neonatal lung disorder']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity5970 :: ('MESH:D011649', 'Disease') :: ['alveolar proteinosis']

answer: @entity8438 :: (MESH:C580477,Disease) :: ['congenital surfactant deficiency']


abstract: OBJECTIVE: @entity1121 is underscored by profound phenotypic and genotypic heterogeneity. Echocardiographically, @entity1121 can be categorized into four morphological subtypes: reverse curve, sigmoidal, neutral contour, and apical variant. Previous studies indicate that reverse curve @entity1121 is the strongest predictor of a positive genetic test. Little is known about the spectrum and prevalence of mutations and genotype-phenotype correlations in apical @entity1121 . DESIGN: Between 1999 and 2007, 1053 @entity1 with the diagnosis of @entity1121 (60% male, age at diagnosis 44.4    19 years) underwent sarcomeric genetic testing. Blinded to the genetic test results, each echocardiogram was scored for septal morphology and phenotyping was performed using the @entity1 's medical record. Subset analysis was performed to elucidate the genotype, phenotype, and outcome of apical @entity1121 . RESULTS: Overall, 71 @entity1 (7%) had apical @entity1121 on echocardiography (63% male, mean age 47.8    15 years, mean left ventricular wall thickness 19.8    6   mm). @entity3585 was uncommon (seven @entity1 ; 10%). Eighteen @entity1 (25%) had a positive genetic test, with the majority of mutations found in @entity18963 (six; 35%) and @entity9741 (six; 35%). Follow-up was available on 68 @entity1 (96%) with a median age of 57.3 years (range 19.3-82 years). Mean follow-up was 5.5 years (range 0.1-18.2 years). There was no statistical difference between the occurrence rates of adverse events between genotype-positive and genotype-negative groups. CONCLUSIONS: In this largest cohort of @entity1 with genetic testing for @entity1121 , <10% exhibited @entity66 . This least common subtype was associated with a negative genetic test result 75% of the time. In contrast to prior publications suggesting a predilection for @entity42696 / @entity10858 mutations in @entity1 with apical @entity1121 , the two most common genotypes ( @entity18963 -HCM and @entity9741 -HCM) remained most common among @entity1 who had a positive genetic test.

title: Genotype-Phenotype Correlations in Apical Variant XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3585 :: ('MESH:D014694', 'Disease') :: ['Left ventricular outflow tract obstruction']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['apical disease']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['Hypertrophic cardiomyopathy', 'hypertrophic cardiomyopathy']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['Hypertrophic Cardiomyopathy']


abstract: Recently, @entity21168 ) has been isolated from new @entity291 arrivals to feedlots, but the association between respiratory and @entity281 with @entity21168 in feedlot @entity291 remains uncertain. Fecal and nasal swab samples from 85 Ohio Agricultural Research and Development Center (OARDC) feedlot @entity291 averaging 7 months of age were collected at arrival (0) and at 4, 7, 14, and 21 days postarrival ( @entity16771 ). An antigen capture enzyme-linked immunosorbent assay (ELISA) was used to detect concurrent shedding of @entity21168 in fecal and nasal samples. All samples ELISA positive for @entity21168 were matched with an equal number of @entity21168 ELISA-negative samples and analyzed by reverse transcription-polymerase chain reaction (RT-PCR) of the N gene. Paired sera were collected at arrival and 21 @entity16771 and tested for antibodies to @entity21168 using an indirect ELISA. Information on clinical signs, treatments provided, and @entity291 weights were collected. The overall rates of @entity21168 nasal and fecal shedding were 48% (41/85) and 53% (45/85) by ELISA and 84% (71/85) and 96% (82/85) by RT-PCR, respectively. The peak of @entity21168 nasal and fecal shedding occurred at 4 @entity16771 . Thirty-two @entity291 (38%) showed concurrent enteric and nasal shedding detected by both tests. Eleven percent of cattle had antibody titers against @entity21168 at 0 @entity16771 and 91% of @entity291 seroconverted to @entity21168 by 21 @entity16771 . The @entity21168 fecal and nasal shedding detected by ELISA and RT-PCR were statistically correlated with ELISA antibody seroconversion (P < 0.0001); however, @entity21168 fecal and nasal shedding were not significantly related to clinical signs. Seroconversion to @entity21168 was inversely related to average daily weight gains (P < 0.06). Twenty-eight respiratory and 7 enteric @entity21168 strains were isolated from nasal and fetal samples of 32 @entity291 in HRT-18 cell cultures. These findings confirm the presence of enteric and respiratory @entity21168 infections in feedlot @entity291 . Further studies are needed to elucidate the differences between enteric and respiratory strains of @entity21168 and their role in the @entity291 @entity1576 complex of feedlot @entity291 .

title: Detection of respiratory and enteric shedding of @entity291 coronaviruses in XXXX in an Ohio feedlot.

entities_list: @entity21168 :: ('11128', 'Species') :: ['BCV', 'bovine coronavirus (BCV']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['enteric infections']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory disease']

entities_list: @entity291 :: ('9913', 'Species') :: ['cattle', 'bovine', 'calves']

answer: @entity291 :: (9913,Species) :: ['cattle']


abstract: OBJECTIVES: To study @entity29 in transfemorally placed endoluminal grafting (TPEG) for @entity1028 , and any relation to cytokine response or @entity86 . DESIGN: Prospective not randomised. University hospital setting. MATERIAL: Fourteen cases of conventional surgery and 23 cases of endovascular technique for @entity1028 repair. METHODS: Tonometry was used for sigmoid colon pH, and ELISAs for serum @entity650 . RESULTS: Mucosal pH in the sigmoid colon fell significantly during clamping and reperfusion in both groups. Lowest measured sigmoid colon pH was 7.10 in the open group, compared to 7.22 in the TPEG group (p < 0.05). The @entity650 levels in serum peaked after 4 h of reperfusion; 249 pg/ml in the open group, compared to 89 pg/ml in the TPEG group (p < 0.05). High levels of @entity650 in the postoperative period and persisting low sigmoidal pH were associated with serious complications. Postoperative temperature did not differ significantly between the groups, and no significant correlation could be found with sigmoid colon pH or @entity650 levels. CONCLUSIONS: The less pronounced perioperative @entity29 in TPEG @entity1 indicates an advantage of the TPEG technique. Splanchnic ischaemia was not related to @entity86 , nor the @entity650 or TNF response.

title: @entity86 , XXXX and cytokine response to @entity1028 repair--a comparison between endovascular and open surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel ischaemia']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative fever']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysms', 'infrarenal abdominal aortic aneurysm']

answer: @entity29 :: (MESH:D015212,Disease) :: ['bowel ischaemia']


abstract: OBJECTIVE: To examine the reproducibility and responsiveness of two often-used instruments for caregiver burden: the Caregiver Strain Index and the Caregiver Reaction Assessment. DESIGN: Repeated administration of self-report questionnaires three years post @entity64 . SUBJECTS: Convenience sample of partners of @entity64 @entity1 . METHODS: Weighted kappa and percentage agreement at item level and intraclass correlations (ICCs) for subscale and total scores. Responsiveness was expressed as smallest detectable difference (SDD) and @entity2246 ( @entity2246 ). RESULTS: Reproducibility of the total Caregiver Strain Index score (N = 26) was very good (0.93; 95% confidence interval 0.84-0.97). For the Caregiver Reaction Assessment (N = 21), the subscales disrupted schedule, financial problems and health problems showed sufficient reproducibility (ICC 0.79-0.86), but the ICCs of the subscales lack of family support (0.67) and self-esteem (0.58) were insufficient. Relating the SDD and @entity2246 to the standard deviation and maximum scale range, responsiveness appears moderate for the Caregiver Strain Index and unsatisfactory for the Caregiver Reaction Assessment. CONCLUSION: The Caregiver Strain Index showed good reproducibility and moderate responsiveness. The Caregiver Reaction Assessment showed insufficient reproducibility and responsiveness.

title: Reproducibility of the Caregiver Strain Index and the Caregiver Reaction Assessment in partners of XXXX @entity1 living in the Dutch community.

entities_list: @entity2246 :: ('MESH:D008661', 'Disease') :: ['SEM', 'standard error of measurement']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: Articular cartilage defects of the knee are a common condition diagnosed at arthroscopy. The management of these @entity75 is controversial. We present our experience using @entity505 fibre implants to repair these defects in 18 @entity1 . Eleven @entity1 (61 per cent) had an osteochondral defect of the medial femoral condyle. Two @entity1 had isolated @entity154 . The mean knee assessment and functional scores were 75 and 80 respectively using The Knee Society Clinical Rating System. Serial post-operative M.R.I. scanning revealed that there was no loss of implant position with an extensive local tissue response and good joint congruity. Overall, 11 @entity1 (61 per cent) returned to their normal sporting activity, while 3 @entity1 (18 per cent) had a poor result. One of these underwent a patellectomy. We conclude that @entity505 fibre implants may have a role to play in the management of @entity4713 of the femoral condyles.

title: Role of @entity505 fibre implants in XXXX of the knee.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['patellar defects']

entities_list: @entity4713 :: ('MESH:D010007', 'Disease') :: ['osteochondral defects']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['osteochondral lesions']

answer: @entity4713 :: (MESH:D010007,Disease) :: ['osteochondral defects']


abstract: PURPOSE: Methods accurately categorizing the diverse biology of @entity263 are needed. A positive baseline reverse transcriptase-PCR for @entity1486 (RT-PCR PSA) in the @entity342 -independent setting is an independent prognostic marker of survival. The objectives of the current study were to examine the prognostic implication of baseline RT-PCR PSA positivity during treatment with an active chemotherapeutic agent and explore whether an RT-PCR PSA "response" provides prognostic information. MATERIALS AND METHODS: In a combined analysis of a phase I and a randomized phase II trial of @entity19878 (an @entity14514 analogue), 104 @entity1 with @entity263 had whole blood samples collected at baseline, then with each cycle of therapy. RT-PCR PSA was assessed and related to @entity1054 ( @entity1054 ). RESULTS: From 100 evaluable @entity1 , 368 samples were received, of which 90.8% were evaluable for RT-PCR PSA status. Baseline RT-PCR PSA status was significantly associated with @entity1054 (hazard ratio, 2.22; 95% confidence interval, 1.40-3.52). Twenty-six of 38 @entity1 positive at first assessment had at least one follow-up RT-PCR PSA that was negative ("response"). In univariate analysis, RT-PCR PSA response was not significantly associated with @entity1054 , but in multivariate analysis, RT-PCR PSA response was of borderline statistical significance in predicting @entity1054 (hazard ratio, 0.41; 95% confidence interval, 0.16-1.01). CONCLUSION: These results provide further confirmation that baseline RT-PCR PSA is a statistically significant predictor of @entity263 . Moreover, this is the first report to suggest that RT-PCR PSA response during chemotherapy treatment may predict @entity1054 .

title: Prognostic significance of baseline reverse transcriptase-PCR for @entity1486 in @entity1 with XXXX treated with chemotherapy.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['TTP in hormone-refractory prostate cancer', 'prostate cancer', 'hormone-refractory prostate cancer']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

entities_list: @entity14514 :: ('MESH:C093788', 'Chemical') :: ['epothilone B']

answer: @entity263 :: (MESH:D011471,Disease) :: ['hormone-refractory prostate cancer']


abstract: BACKGROUND: @entity19316 ( @entity1597 ) is one of the most important active ingredients of a Chinese herb Ligusticum wallichii Franchat, which is widely used in many @entity63 disorders treatments. However, the exact mechanism by which @entity1597 protects the @entity2759 /reperfusion (I/R) injury is still unknown. For this purpose, @entity95 were randomly divided into sham group, control group and @entity1597 group. After the evaluation of neurologic function, the spinal cords were immediately removed for biochemical and histopathological analysis. Apoptosis was measured quantitatively by the terminal transferase UTP nick end-labeling (TUNEL) method and confirmed by electron microscopic examination, the expression of @entity9471 and @entity9470 was immunohistochemically evaluated and quantified by Western blot analysis. RESULTS: Neurologic outcomes in the @entity1597 -group were significantly better than those in the control group (P < 0.05). @entity1597 decreased spinal cord @entity1234 ( @entity1865 ) levels and ameliorated the down regulation of spinal cord @entity224 dismutase (SOD) activity. @entity1597 significantly reduced the @entity393 and TUNEL-positive rate. Greater @entity9470 and attenuated @entity9471 expression was found in the @entity1597 treating @entity95 . CONCLUSION: These findings suggest that @entity1597 has protective effects against spinal cord I/R injury by reducing apoptosis through regulating @entity9470 and @entity9471 expression.

title: Anti-apoptotic and neuroprotective effects of @entity19316 following @entity2759 in XXXX .

entities_list: @entity19316 :: ('MESH:C017953', 'Chemical') :: ['Tetramethylpyrazine']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity2759 :: ('MESH:D020760', 'Disease') :: ['spinal cord ischemia']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of motoneurons']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: BACKGROUND: To compare the efficacy of the Newcastle @entity1 dialysis and ultrafiltration system (Nidus) with @entity298 ( @entity298 ) and conventional haemodialysis (HD) in @entity1 weighing <8 kg. METHODS: We compared the @entity1133 , @entity1011 and @entity1391 clearances, the ultrafiltration precision, and the safety of the Nidus machine with @entity298 in 7 piglets weighing 1-8 kg, in a planned randomised cross-over trial in babies, and in babies for whom no other therapy existed, some of whom later graduated to conventional HD. RESULTS: Two babies entered the randomised trial; 1 recovered rapidly on @entity298 , the other remained on the Nidus as @entity298 failed. Additionally, 9 babies were treated on the Nidus on humanitarian grounds: 3 because of failed @entity298 , and 3 with permanent @entity177 later converted to conventional HD. We haemodialysed 10 babies weighing between 1.8 and 5.9 kg for 2,475 h during 354 Nidus sessions without any clinically important incidents, and without detectable haemolysis. Single-lumen vascular access was used with no blood priming of circuits. The @entity1133 , @entity1011 and @entity1391 clearances using the Nidus were around 1.5 to 2.0 ml/min in piglets and babies, and were consistently higher than @entity298 clearances, which ranged from about 0.2 to 0.8 ml/min (p    <=   0.0002 for each chemical). Ultrafiltration was achieved to microlitre precision by the Nidus, but varied widely with @entity298 . Fluid removal using conventional HD was imprecise and resulted in some hypovolaemic episodes requiring correction. CONCLUSION: The Nidus can provide HD in the Pediatric Intensive Care Unit (PICU) and outpatient intermittent HD without blood priming for babies weighing <8 kg, It generates higher dialysis clearances than @entity298 , and delivers more precise ultrafiltration control than either @entity298 or conventional HD.

title: Haemodialysing babies weighing <8 kg with the Newcastle XXXX dialysis and ultrafiltration system (Nidus): comparison with peritoneal and conventional haemodialysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['infants', 'infant']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['kidney failure']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD']

answer: @entity1 :: (9606,Species) :: ['infant']


abstract: Electro-corticographic tracings (two longitudinal leads, @entity162 ) were recorded from curarized @entity95 (5/group) receiving selective internal carotid artery injections of either @entity61846 , a new non-ionic contrast medium, or @entity6111 , the high osmolar diatrizoate or hypertonic @entity2656 (isotonic to the non-ionic agents). A further group was submitted to the surgical preparation but was not injected. The solutions were injected at a dose of 2.5 ml during 30 seconds. The animals were anaesthetized ( @entity1508 ) during the surgical period. The permeability of the blood-brain barrier was assessed by means of the extravasation of Evans'blue. Tracings were visually assessed and a semi-quantitative method for blind evaluation of fast/slow rhythms was used. This method was pharmacologically validated by the use of @entity4485 and @entity5093 . @entity4946 and @entity6111 induced respectively 3 and 2 paroxystic tracings during or immediately after the injection period. @entity61846 and hypertonic @entity2656 did not cause such effect. Paroxystic tracings in the @entity6111 group were not associated with extravasation of Evans'blue in the cerebral parenchyma. Blood brain barrier was disrupted in all @entity95 receiving the high osmolar agent diatrizoate. Tracings of the control group were characterized by a progressive increase of fast rhythms, as those of the @entity61846 and @entity2656 groups. On the contrary, @entity6111 and especially @entity4946 induced an increase in the proportion of slow waves. Taken together, these data suggest that @entity61846 shows an excellent tolerability potential for clinical use.

title: [Electrocorticographic evaluation of the neurologic tolerability of XXXX (Xenetix), a new non-ionic contrast medium in @entity95 ].

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol']

entities_list: @entity4485 :: ('MESH:D010424', 'Chemical') :: ['pentobarbital']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar assembly']

entities_list: @entity1508 :: ('MESH:D006221', 'Chemical') :: ['halothane']

entities_list: @entity4946 :: ('MESH:D003973', 'Chemical') :: ['Diatrizoate', 'diatrizoate']

entities_list: @entity61846 :: ('MESH:C093233', 'Chemical') :: ['iobitridol', 'Iobitridol']

entities_list: @entity5093 :: ('MESH:D010433', 'Chemical') :: ['pentylenetetrazole']

answer: @entity61846 :: (MESH:C093233,Chemical) :: ['iobitridol']


abstract: Inhomogeneous magnetic fields are used in magnetic traps to levitate biological specimens by exploiting the natural diamagnetism of virtually all materials. Using @entity375 , this report investigates whether magnetic field (B) induces changes in growth, cell cycle, and gene expression. Comparison to the effects of gravity and temperature allowed determination of whether the responses are general pathways or stimulus specific. Growth and cell cycle analysis were examined in wild-type (WT) @entity375 and strains with deletions in transcription factors @entity28165 or @entity61091 . @entity28165 , @entity61091 , and @entity18680 have been implicated in responses to physical forces, but only @entity28165 and @entity61091 deletions are viable. Gene expression changes were examined in strains bearing GFP-tagged reporters for YIL052C ( @entity61091 -dependent), @entity61092 ( @entity61091 / @entity18680 -dependent), or @entity60331 ( @entity28165 -dependent). The cell growth and gene expression responses were highly stimulus specific. B increased growth only following @entity28165 or @entity61091 deletion, associated with decreased G1 and G2/M and increased S phase of the cell cycle. In addition, B suppressed expression of both YIL052C and YST2. Gravity decreased growth in an @entity61091 but not @entity28165 -dependent manner, in association with decreased G2/M and increased S phase of the cell cycle. Additionally, gravity decreased expression of @entity60331 and YIL052C genes. Temperature increased cell growth in an @entity28165 - and @entity61091 -dependent manner in association with increased G1 and G2/M with decreased S phase of the cell cycle. In addition, temperature increased YIL052C gene expression. This study shows that B has selective effects on cell growth, cell cycle, and gene expression that are stimulus specific.

title: Diamagnetic levitation changes growth, cell cycle, and gene expression of XXXX .

entities_list: @entity375 :: ('4932', 'Species') :: ['yeast', 'Saccharomyces cerevisiae']

answer: @entity375 :: (4932,Species) :: ['Saccharomyces cerevisiae']


abstract: OBJECTIVE: To describe the utilization and findings with a statewide, prehospital spine-assessment protocol for @entity341 ( @entity341 ) providers in a rural state. METHODS: The study was a prospective sample of @entity341 @entity1 evaluated by prehospital providers for @entity130 during a one-year investigation period. Prehospital providers prospectively completed supplementary spine data-collection forms that reported @entity1 demographics and @entity341 provider findings with the spine-assessment protocol. Data were analyzed using descriptive statistics. RESULTS: There were 207,545 @entity341 encounters during the study period, including 31,885 transports for acute @entity130 -related illness. Prehospital providers provided spine-assessment forms for 2,220 @entity1 encounters. Providers reported a decision to immobilize 1,301 (59%) @entity1 . For these immobilized @entity1 , spine protocol findings included 416 (32%) @entity1 deemed as unreliable, 358 (28%) with distracting injury, 80 (6%) with an abnormal neurologic examination, and 709 (54%) with spine @entity158 or @entity925 . Linkage of @entity341 and hospital data revealed seven acute spine @entity174 @entity1 among the 2,220 reported encounters, all of whom were immobilized by @entity341 providers. CONCLUSIONS: Use of this prehospital spine-assessment protocol resulted in an @entity341 provider decision not to immobilize approximately 40% of @entity341 @entity130 @entity1 . Few spine @entity174 @entity1 were encountered during the investigational period, though all were immobilized.

title: XXXX provider findings and interventions with a statewide @entity341 spine-assessment protocol.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency medical services', 'EMS']

entities_list: @entity925 :: ('MESH:D063806', 'Disease') :: ['tenderness']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma-related injury', 'trauma']

answer: @entity341 :: (MESH:D004630,Disease) :: ['EMS']


abstract: BACKGROUND/PURPOSE: The efficacy of the rapid semi-quantitative @entity1904 (PCT) test for the diagnosis of @entity2348 was evaluated in @entity1 with @entity1850 . METHODS: A retrospective observational study was performed from June to December 2008 at the Chugoku Rosai General Hospital, Japan. This study analyzed consecutive @entity1 (both outpatients and inpatients) who developed @entity1850 and whose PCT test was measured semi-quantitatively within 24 hours of onset, or at the first hospital visit. Based on the clinical diagnosis, the @entity1 were divided into two groups. Group I comprised @entity1 with a @entity2348 , and group II comprised @entity1 with a @entity2348 . Receiver operating characteristic curves were used to evaluate the diagnostic value of the semi-quantitative PCT test kit, @entity1851 levels and white blood cells counts for the detection of @entity2348 , and the areas under the resulting curves were compared. RESULTS: A total of 168 @entity1 were included and divided into groups I (n=112) and II (n=56). Group I showed a significantly higher percentage of positive PCT tests (>=  0.5 ng/mL) than group II (67.8%vs. 19.6%, p < 0.001). PCT showed a sensitivity of 67.8% [95% confidence interval (CI)=58.4-76.4] and a specificity of 80.4% (95% CI=67.6-89.8). The areas under the resulting curves for PCT (0.764) were significantly larger than those seen for @entity1851 (0.650, p=0.02) and white blood cells (0.618, p=0.006). CONCLUSION: The semi-quantitative PCT test is as useful for distinguishing @entity2348 from other @entity32 in common clinical practice as the quantitative PCT.

title: Semi-quantitative XXXX test for the diagnosis of @entity2348 : clinical use and experience in Japan.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory diseases']

entities_list: @entity1904 :: ('MESH:C029100', 'Chemical') :: ['procalcitonin']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections', 'bacterial infection', 'non-bacterial infection, or non-infectious disease']

entities_list: @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity1904 :: (MESH:C029100,Chemical) :: ['procalcitonin']


abstract: OBJECTIVE: To observe the early outcome of @entity2213 in the treatment of @entity1860 ( @entity1860 ). METHODS: There were 54 @entity1860 @entity1 including 17 @entity1 in @entity2212 ( @entity2212 ), 13 @entity1 in accelerated phase (AP) and 24 @entity1 in @entity9638 ( @entity9638 ). The dosage of @entity2213 is 400 mg/day for @entity2212 @entity1 and 600 mg/day for AP and @entity9638 @entity1 . The prescribed dose was administrated orally, once daily after a meal with a large glass of water. Before starting the @entity2213 administration, all the @entity1 had thorough physical examination as well as blood and bone marrow examination, Ph chromosome and or the bcr/abl fusion-gene detection. Blood picture was examined twice a week in the first month of administration and thereafter weekly or fortnightly in the following days. Hepatic and renal function was tested fortnightly or every four weeks. @entity1 had bone marrow examination, Ph chromosome and or the bcr/abl fusion-gene detection again when they achieved a hematological response (CR). Dose was adjusted from time to time according to the results of blood examination and the @entity1 tolerance to the drug. RESULTS: After a median 5-month period of follow-up, all the 17 @entity2212 @entity1 achieved complete hematological response, including 6 cases (35.2%) whose Ph chromosome turned negative after treatment. 8 (61.5%) out of the 13 AP @entity1 and 9 (37.5%) out of the 24 @entity9638 @entity1 returned to @entity2212 respectively. Adverse events included myelosuppression, periorbital @entity4 or @entity4 of the lower limbs, @entity925 and muscle cramps, @entity390 , @entity391 , low fever, tetter and @entity648 increasing. CONCLUSIONS: @entity2213 has good early efficacy in the treatment of @entity1860 and the therapeutic result is the best in the @entity2212 @entity1 , next in the AP @entity1 and relatively poor in the BP @entity1 . The long term outcome of @entity2213 needs further observation. @entity1 have a good tolerance to @entity2213 .

title: [The early efficacy of XXXX in the treatment of 54 cases of @entity1860 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2212 :: ('MESH:D015466', 'Disease') :: ['chronic phase', 'CP']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity9638 :: ('MESH:D001752', 'Disease') :: ['blast crisis', 'BC']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']

answer: @entity2213 :: (MESH:C097613,Chemical) :: ['imatinib']


abstract: We report two cases of primary @entity2184 with metastatic involvement of the contralateral eye. Two female @entity1 presented with primary @entity320 . In the first case, primary enucleation of the affected eye was performed. Two years later, systemic @entity5 spread with contralateral @entity320 was detected. A decision for observation of the ocular @entity3 was made. In the second case, systemic @entity5 spread was already evident at time of initial diagnosis of the @entity320 . Six months later, a choroidal @entity3 was detected in the fellow eye. Again, observation was recommended. In conclusion, systemic spread of primary @entity320 may include a choroidal @entity3 to the contralateral eye. Observation of the second affected eye may be prescribed.

title: Treatment considerations for primary XXXX with choroidal metastasis to the fellow eye.

entities_list: @entity2184 :: ('MESH:C536494', 'Disease') :: ['uveal melanoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['choroidal melanoma', 'ocular melanoma']

answer: @entity2184 :: (MESH:C536494,Disease) :: ['uveal melanoma']


abstract: BACKGROUND: The Casting for Recovery   therapeutic intervention provides a positive, nontraditional weekend experience for @entity0 survivors. @entity1 receive @entity238 fishing instruction and participate in structured and unstructured therapeutic activities.   . OBJECTIVES: The aim of this study was to evaluate whether @entity0 survivors had improved resilience and quality-of-life scores after program participation.   . METHODS: @entity1 completed the Quality of Life @entity0 questionnaire and Connor-   Davidson Resilience Scale two weeks before and three and six months after the retreats.   . FINDINGS: No statistically significant differences between pre- and postintervention quality-of-life or resilience scores were noted. However, qualitative data reflected a high degree of @entity1 satisfaction, healing, and learning. @entity1 added that peer and volunteer connections, group camaraderie, good nutrition, being in nature, and learning a new skill were all positive aspects of the program.

title: Quality of Life and Resilience: Exploring a @entity238 Fishing Intervention for XXXX   .

entities_list: @entity1 :: ('9606', 'Species') :: ['participant', 'Participants']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast Cancer', 'breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer Survivors']


abstract: PURPOSE: To determine whether single nucleotide polymorphisms (SNPs) of genes coding for matrix metalloproteinases (MMPs) and the @entity22667 receptor gene ( @entity31416 ) are related to a response to latanoprost in a white Spanish population of glaucomatous @entity1 . DESIGN: Case-control study. @entity1 : One hundred twenty-four @entity1 with @entity1538 . METHODS: Genotyping was performed in 117 @entity1 with primary @entity1538 with a minimum treatment duration of 4 weeks. Candidate genes and individual polymorphisms were selected according to the effect on the mechanism of action of latanoprost. Multi-SNP haplotype analyses for associations also were tested. MAIN OUTCOME MEASURES: Diurnal intraocular pressure reduction and genotyping of the SNPs in the MMPs and @entity31416 . RESULTS: The @entity31416 SNPs were associated with positive ( @entity59765 , @entity59766 ) and negative ( @entity59767 , @entity59768 , @entity59769 ) responses to latanoprost. Multiple testing found 2 genes, @entity31416 and @entity3334 , were related to refractoriness to latanoprost. CONCLUSIONS: The SNPs of the @entity31416 and @entity3334 genes may determine the latanoprost response in a white European Spanish population. This study identified 5 SNPs related to the latanoprost response; 1 SNP, @entity59767 , already has been associated with a poor response to latanoprost in a healthy Japanese population. Latanoprost is a commonly used antiglaucomatous drug, and increased knowledge of its mechanism of action will lead to advances in pharmacogenetics.

title: Association between SNPs of Metalloproteinases and Prostaglandin F2a Receptor Genes and Latanoprost Response in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma']

entities_list: @entity22667 :: ('CHEBI:15553', 'Chemical') :: ['prostaglandin F2a']

answer: @entity1538 :: (MESH:D005902,Disease) :: ['Open-Angle Glaucoma']


abstract: UNASSIGNED: OBJECTIVE @entity1 with @entity7026 (AVMs) commonly present with @entity410 . @entity410 outcomes in @entity1 treated with stereotactic radiosurgery (SRS) are poorly defined. A case series of @entity1 with cerebral AVMs treated with SRS is presented to evaluate long-term @entity410 outcome. METHODS A retrospective review of the medical record was performed, identifying 204 consecutive @entity1 with AVMs treated with SRS between January 1991 and June 2012. Clinical and radiographic data were evaluated. @entity410 outcome was measured using the Engel Epilepsy Surgery Outcome Scale. Mean duration of follow-up was 37.1 months (SD 38.3 months) with a minimum follow-up period of 1 month. RESULTS Of the 204 @entity1 with cerebral AVMs treated with SRS, 78 @entity1 (38.2%) presented with @entity410 and 49 of those @entity1 were treated with @entity734 ( @entity734 ). Following SRS, 63 (80.8%) of the 78 @entity1 who had had @entity410 prior to SRS were @entity410 -free at a mean follow-up time of 37.2 months (SD 41.3 months). Of the 49 @entity1 who had been treated with @entity734 , 17 were still taking @entity734 at last follow-up. Of the 126 @entity1 who did not present with @entity410 prior to treatment with SRS, only 5 @entity1 (4.0%) had @entity410 in the post-SRS period. There was no significant correlation between post-SRS @entity410 status and @entity1 demographic features, comorbidities, @entity7026 characteristics, history of operative intervention, pre- or posttreatment @entity548 , or radiographic degree of @entity7026 resolution. CONCLUSIONS Stereotactic radiosurgery for treatment of cerebral AVMs is effective at providing long-term control of @entity410 . A substantial number of @entity1 who were treated with SRS were not only @entity410 free at their last follow-up, but had been successfully weaned from antiepileptic medications.

title: @entity410 outcomes after stereotactic radiosurgery for the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity7026 :: ('MESH:D002538', 'Disease') :: ['cerebral arteriovenous malformations', 'AVM']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'Seizure']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['AEDs', 'antiepileptic drugs']

answer: @entity7026 :: (MESH:D002538,Disease) :: ['cerebral arteriovenous malformations']


abstract: The prevention of implant-related @entity281 is an important issue in medical research. The aim is to exploit the strong antimicrobial effect of @entity575 nanoparticles (AgNP) to develop new antibacterial coatings for implants. However, there is still a serious lack of information on the influence of AgNP on bone metabolism. In the present study we have evaluated the influence of AgNP on cell stress, viability, proliferation and differentiation of primary @entity1 mesenchymal stem cells (MSC) and osteoblasts (OB). Finally, cellular uptake of the AgNP was examined. After 21 days impairment of cell viability of MSC and OB occurred at a concentration of 10  g/g of AgNP. @entity137 and inhibition of proliferation was highly time and dose dependent. No influence on cell differentiation, but an increase in cell stress, was observed. Uptake of AgNP into MSC and OB could be confirmed. In summary, these results demonstrate AgNP-mediated @entity137 at higher concentrations. Therefore, a therapeutical window for the application of AgNP in medical products might exist. However, the antibacterial benefits and potential health risks of AgNP need to be weighed in further studies.

title: Biocompatibility of XXXX nanoparticles and @entity575 ions in primary @entity1 mesenchymal stem cells and osteoblasts.

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Cytotoxicity', 'cytotoxicity']

answer: @entity575 :: (MESH:D012834,Chemical) :: ['silver']


abstract: This study was designed to evaluate the characteristics of @entity1 orbital fat and connective tissue. Two exenteration specimens were studied by light microscopy with special stains. Four distinct regions were identified on the basis of their connective tissue septa, which contained blood vessels and were composed of @entity2362 and collagen types I, III, and IV. Transmission electron microscopy was performed on the opposite orbits. The fibroblasts and adipocytes appeared metabolically inactive and showed no regional differences. The fat was phase extracted from the connective tissue and subjected to biochemical analysis. No regional differences were found in the content of @entity1718 and protein. The @entity1718 included @entity7609 (22-24.6%), @entity3952 (45-51.5%), and @entity4722 (15-18.6%). Despite demarcation of the orbital fat into distinct regions by the connective tissue septa, ultrastructural and biochemical analysis revealed no regional variations in the fat. The diagnostic and therapeutic implications of these findings are discussed.

title: Characterization of XXXX orbital fat and connective tissue.

entities_list: @entity3952 :: ('MESH:D019301', 'Chemical') :: ['oleic acid']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity4722 :: ('MESH:D019787', 'Chemical') :: ['linoleic acid']

entities_list: @entity7609 :: ('MESH:D019308', 'Chemical') :: ['palmitic acid']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: INTRODUCTION: Studies of recurrent @entity1165 and @entity2224 (VT/VF) have been limited to "electrical storms," where recurrent @entity943 necessitate repeated external cardioversions or defibrillations. @entity1 with an @entity737 ( @entity737 ) may also suffer frequently recurrent @entity943 . The aim of this study was to analyze the temporal pattern and the clinical relevance of clustering @entity943 in @entity737 recipients. METHODS: The incidence and the type of @entity943 were determined by reviewing stored electrograms. @entity2224 were defined as the occurrence of three or more adequate and successful @entity737 interventions within 2 weeks. Two hundred and fourteen consecutive @entity737 recipients were followed during an average of 3.3 +/- 2.2 years (698 @entity1 -years). RESULTS: Fifty-one @entity1 (24%) suffered 98 @entity2224 21 +/- 22 months after @entity737 implantation, 93% of these clusters consisting of recurrent regular VT. Monomorphic VT as index event leading to @entity737 implantation was the only factor predicting @entity2224 . Kaplan-Meier estimates of the combined end-point of @entity204 or heart transplantation showed a 5-year event-free survival of 67% versus 87% in @entity1 with and without clusters, respectively (P = 0.026). Adjusted hazard ratios for @entity204 or heart transplantation in the group with @entity943 clusters was 3.5 (95% confidence interval 1.5-7.9 P = 0.003). CONCLUSIONS: @entity2224 are frequent late after @entity737 implantation particularly in @entity1 who had VT as index-event. As @entity943 and recurrent @entity737 interventions are responsible for an important morbidity, there is a possible role for a prophylactic intervention. Furthermore, @entity2224 are an independent marker of increased risk of @entity204 or need for heart transplantation.

title: Characteristics and relevance of clustering XXXX in defibrillator recipients.

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter-defibrillator']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation', 'VT/VF clusters']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias', 'arrhythmias', 'arrhythmia']

answer: @entity943 :: (MESH:D001145,Disease) :: ['ventricular arrhythmias']


abstract: BACKGROUND: The clinical characteristics of @entity10469 are only partially defined. More than 50% of @entity1 with high levels of ganglionic @entity934 receptor (AChR) autoantibodies have a combination of sicca complex (marked @entity936 and @entity2133 ), abnormal pupillary light response, upper @entity344 , and @entity1494 . OBJECTIVE: To compare @entity1 with @entity4148 who were seropositive (n = 19) and seronegative (n = 87) for ganglionic AChR antibodies. DESIGN: Retrospective review of autonomic programmatic database. SETTING: Autonomic Disorders Program Project at Mayo Clinic College of Medicine, Rochester, Minn. @entity1 : We evaluated a cohort of 87 @entity1 with @entity4148 who had undergone full autonomic testing and neurological evaluation and who had a complete panel of paraneoplastic and ganglionic AChR antibodies. We compared @entity1 seropositive (n = 19) and seronegative (n = 87) for ganglionic AChR antibodies. RESULTS: The seropositive group had a significant overrepresentation of abnormal pupillary responses (12/18 [67%] vs 12/87 [14%]; P<.001), sicca complex (9/15 [60%] vs 11/47 [23%]; P =.01), and @entity344 (16/19 [84%] vs 48/85 [56%]; P =.02). A subacute mode of onset was more common in the seropositive group (12/19 [63%] vs 23/84 [27%]; P =.004). Results of quantitative autonomic function tests differed significantly in the 2 groups only in the cardiovagal domain. Because subacute onset was overrepresented in the seropositive group, we analyzed the data separately, controlling for temporal profile (ie, the relationship between antibody status and symptoms while controlling for rate of onset). The relationships between antibody status and clinical profile (eg, presence of sicca complex, @entity2300 , and lower @entity344 ) generally remained significant regardless of onset rate, indicating that the associations are not due to temporal profile. CONCLUSIONS: These observations support the concept that ganglionic AChR antibodies are diagnostically and pathophysiologically important. @entity1 with @entity551 and prominent cholinergic @entity8053 are most likely to be seropositive for ganglionic AChR antibody.

title: @entity4148 : comparison of cases seropositive and seronegative for ganglionic XXXX receptor antibody.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['neurogenic bladder']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['lower gastrointestinal tract dysautonomia', 'gastrointestinal tract symptoms']

entities_list: @entity4148 :: ('MESH:D001342', 'Disease') :: ['idiopathic autonomic neuropathy']

entities_list: @entity10469 :: ('MESH:D020274', 'Disease') :: ['autoimmune autonomic neuropathy']

entities_list: @entity8053 :: ('MESH:D054969', 'Disease') :: ['dysautonomia']

entities_list: @entity2300 :: ('MESH:D011681', 'Disease') :: ['pupillary abnormalities']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['orthostatic hypotension']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity934 :: (MESH:D000109,Chemical) :: ['acetylcholine']


abstract: BACKGROUND/AIMS: The aim of this study was to investigate the frequency of sacroileitis and @entity1691 in @entity29 and the relationship between disease activity, joint symptoms and @entity1530 antigen positivity. METHODS: Sacroiliac joint radiography and three phase bone scanning of 33 @entity31 @entity1 (17 active and 16 in remission) and 29 @entity30 @entity1 (15 active and 14 in remission) was performed. @entity1530 was determined in all @entity1 and 60 control subjects. RESULTS: Sacroileitis was found in 10 out of 33 @entity1 with @entity31 (30. 30%) and seven out of 29 @entity1 with @entity30 (24. 13%). Of these @entity1 , eleven had active (17.73%) disease and six were in remission (9. 68%). The diagnosis of sacroileitis was made by bone radiography in seven @entity1 (41.18%) and by bone scanning in the other 10 @entity1 (58.82%). A diagnosis of @entity1691 was made in three @entity1 (17. 64%) who had previously been diagnosed by bone radiography to have sacroileitis. @entity1530 was positive in six @entity1 (9.67%) with @entity29 and three subjects (5%) of the control group. There were no significant differences between these two groups (p>0.05). Compared to the control group, all three @entity1 with @entity1691 were @entity1530 positive, the difference being significant (p>0. 01). CONCLUSIONS: The clinical course of sacroileitis is independent of the activitiy of @entity29 . Accordingly, @entity1 with @entity29 , especially those with sacroileitis, should be investigated for the presence of @entity1511 .

title: The frequency of sacroileitis and @entity1691 in @entity29 and XXXX association.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity1511 :: ('MESH:D013166', 'Disease') :: ['anklylosing spondylitis']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity1530 :: (3106,Gene) :: ['HLA-B27']


abstract: BACKGROUND: @entity45 are brain cavities resulting from perinatal @entity432 and are commonly associated with severe @entity51 and medically intractable @entity302 . Thirty-seven @entity1 presenting to the University of M  nster with intractable @entity410 because of a @entity9670 cyst were treated by uncapping and fenestration of these cysts to the lateral ventricle between 1978 and 1992. We conducted the following study to determine the efficacy and safety of the uncapping and fenestration procedure for the treatment of @entity410 . METHODS: We reviewed all cases retrospectively and assessed the outcome of these @entity1 with regard to @entity410 , paresis, and perioperative complications. RESULTS: Of 37 @entity1 , 23 (62%) were @entity410 -free postoperatively. Nine @entity1 (24%) had a reduction of @entity410 and five @entity1 (14%) remained unchanged. Of 30 @entity1 with @entity1269 , 11 (30%) improved after the operation. The leading postoperative problem was a subcutaneous/subgaleal cushion of @entity2841 , which affected 12 @entity1 (12 of 37). A dural patch covering the iatrogenic dural defect could not prevent or reduce postoperative @entity2841 leakage, but prolonged the @entity86 period. @entity86 occurred in 36 @entity1 (36 of 37) and was caused by an @entity5827 . CONCLUSIONS: @entity1 with intractable @entity410 and @entity9670 cysts benefit from uncapping and cyst fenestration to the lateral ventricle. Concomitant perioperative complications are mild and are easily treated.

title: Fenestration of @entity9670 cysts to the lateral ventricle: experience with a new technique for treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity9670 :: ('MESH:D065708', 'Disease') :: ['porencephalic']

entities_list: @entity1269 :: ('MESH:D010291', 'Disease') :: ['preoperative hemiparesis']

entities_list: @entity5827 :: ('MESH:D008582', 'Disease') :: ['aseptic meningitis']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficits']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity45 :: ('MESH:D010181', 'Disease') :: ['Porencephalic cysts']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative fever', 'Postoperative fever']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['vascular occlusion']

answer: @entity410 :: (MESH:D012640,Disease) :: ['seizures']


abstract: OBJECTIVE: The aim of this study was to determine whether @entity4044 special extract @entity12689 amplifies the known effects of @entity117 ( @entity1281 ) on @entity1423 , @entity548 time or other coagulation parameters in healthy subjects. METHODS: In a double-blind, double-dummy procedure, 50 healthy male subjects (20-44 years) were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. @entity1281 followed by @entity1281 + @entity12689 or @entity1281 + @entity12689 followed by @entity1281 . Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily ( @entity1281 group: @entity1281 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; @entity1281 + @entity12689 group: @entity1281 500 mg tablet + @entity12689 120 mg-coated tablet in the morning and placebo tablet + @entity12689 120 mg-coated tablet in the evening), resulting in a daily dose of @entity1281 500 mg in the @entity1281 group and 500 mg @entity1281 + 240 mg @entity12689 in the @entity1281 + @entity12689 group. Bleeding time, coagulation parameters and platelet activity in response to various agonists were determined. In addition, adverse events, laboratory variables and vital signs were measured. The primary variable @entity548 time was assessed in confirmatory analysis, all other variables were evaluated descriptively. The coagulation variables were analysed by ANOVA under the crossover model. RESULTS: @entity1281 given alone clearly prolonged @entity548 time. @entity1281 and the combination of @entity1281 + @entity12689 exerted quite similar effects on all coagulation parameters measured, including @entity548 time ( @entity1281 alone: 4.1 min before therapy, 6.2 min after therapy; @entity1281 + @entity12689 : 4.2 min before therapy, 6.3 min after therapy; ratio of means: 1.01, 90% CI 0.86, 1.19) and agonist-induced @entity1423 (collagen-induced @entity1423 - @entity1281 : 84.5% before therapy, 81.0% after therapy; @entity1281 + @entity12689 : 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% CI 0.95, 1.05; @entity857 -induced @entity1423 - @entity1281 : 72.6% before therapy, 47.2% after therapy; @entity1281 + @entity12689 : 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% CI 0.85, 1.06). Both treatments were well tolerated, and both the number and nature of adverse events in the two groups were similar. CONCLUSIONS: Our findings suggest that co-administration of @entity1281 and @entity12689 does not constitute a safety risk, including in an elderly @entity1 population undergoing treatment with @entity12689 .

title: Does XXXX special extract @entity12689 provide additional effects on coagulation and @entity548 when added to @entity117 500 mg daily?

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid']

entities_list: @entity4044 :: ('3311', 'Species') :: ['Ginkgo biloba']

entities_list: @entity857 :: ('MESH:D000244', 'Chemical') :: ['adenosine diphosphate']

answer: @entity4044 :: (3311,Species) :: ['Ginkgo biloba']


abstract: BACKGROUND: @entity5 is a rare disease of the nail apparatus. It is a welldefined @entity5 of 1 cm size in diameter, which originates from glomus cells of glomus bodies. Despite a welldefined clinical picture and histological information, the disease causes @entity4764 and discomfort for @entity1 that may be diagnosed only after several years of repeated inefficient treatment. MATERIALS AND METHODS: In our female @entity1 , three years passed from the onset of the first symptoms of the @entity5 to final diagnosis. The @entity1 had to undergo many tests and examinations, but the final diagnosis was proven on the basis of clinical experience. RESULTS: New findings and knowledge about the diagnosis of @entity5 are relevant for a number of medical fields because the @entity1 with similar problems and unexplained persistent @entity158 of the nail can be treated at various clinical departments.Key words: @entity21342 and fingers The authors declare they have no potential conflicts of interest concerning drugs, products, or   services used in the study. The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers.Submitted: 12. 2. 2015Accepted: 23. 3. 2015.

title: [ XXXX of the finger  - case report].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Glomus tumor', 'glomus tumor']

entities_list: @entity21342 :: ('MESH:D005918', 'Disease') :: ['glomus - glomus tumor - glomus tumor']

entities_list: @entity4764 :: ('MESH:D051346', 'Disease') :: ['longtime difficulties']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Glomus tumor']


abstract: Postoperative outcome and severity of acute @entity2679 in 32 @entity6 @entity1 ( @entity3918 ) who underwent urgent cholecystectomy were compared on a case-control basis with 32 nondiabetic age/sex matched controls. There was no difference in incidence of @entity8 or duration of acute symptoms before surgery. @entity65 were more often seen in the @entity6 group (16/32 in @entity3918 , 7/32 in controls, P = 0.03). Bactobilia was more often in @entity6 (19 in @entity3918 , 11 in controls, p = 0.07). Postoperatively, there was a trend toward higher incidence in overall complication rate. @entity166 (wound and @entity1729 , @entity99 ) were higher in @entity3918 , although the difference was not statistically significant. One @entity1 in @entity3918 group died as a result of @entity177 . There was no difference in total and postoperative hospital stay. The severity of acute @entity2679 was greater in @entity6 (26 @entity1 with moderate-to-severe @entity2679 in @entity3918 group, 18 in control group, P = 0.05). The study indicates that although pathological findings were more severe in @entity3918 group, the postoperative course is comparable in @entity6 as compared to age and sex matched nondiabetic controls. Our findings justify reconsideration of prophylactic cholecystectomy in asymptomatic @entity6 @entity1 .

title: Acute @entity2679 in XXXX @entity1 .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal and lung diseases']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics', 'diabetic']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['multiorgan failure']

entities_list: @entity2679 :: ('MESH:D002764', 'Disease') :: ['cholecystitis']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory infections']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic abscess']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['Infectious complications']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular diseases']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: UNASSIGNED: 4505 Background: S9916 was designed to compare two regimens: @entity2664 / @entity229 (M+P) vs @entity1205 / @entity12749 (D+E), in @entity1 (pts) with @entity263 . Stratification factors were: Progression type: inmeasurable/ evaluable disease vs increasing PSA only; NCI CTC Bone @entity158 scale: Grade >=  2 vs < 2; and SWOG performance status 0-1 vs 2-3. The primary endpoint was survival. 770 pts were accrued. There were 406 deaths. METHODS: Baseline, treatment and follow-up data were compiled for a subset of 499 pts who had a minimum of two PSAs recorded in the first 3 months on-study. 161 (32.3%) had a prior radical prostatectomy. We used Cox regression analysis to test whether PSA velocity was a prognostic factor for mortality independent of treatment (M+P vs D+E) received, adjusting for influential baseline variables. All statistical tests were 2-sided. RESULTS: Initial PSA and prior prostatectomy were associated with mortality and included in all analyses. In an analysis without treatment, PSA velocity was correlated with survival (HR=3.67; 95% CI=(2.72,4.96), p<.0001), with odds of failing nearly quadrupling with a unit increase in PSA velocity. Without adjusting for PSA velocity, treatment was associated with mortality failure rate (HR = 1.39 for M+P vs. D+E, 95% confidence interval (CI)=(1.10,1.75), p=.006). After adjustment for PSA velocity, treatment was no longer associated with mortality (HR = 1.15 for M+P vs. D+E, 95% CI=(.91,1.46), p=.23), while PSA velocity was still significant (HR = 3.56, 95% CI=(2.62,4.83), p<.0001). @entity1 with a prior prostatectomy had a failure rate nearly half that for @entity1 without prior prostatectomy (HR=.55, 95% CI=(.42,.72), p<.0001), and HR that less than doubled with a unit increase in PSA velocity (HR=1.69, 95% CI=(1.02,2.79), p=.0003). CONCLUSIONS: PSA velocity measured during the first 3 months of chemotherapy provides independent prognostic information to treatment and should be further investigated as a surrogate endpoint for mortality in future trials of chemotherapeutic regimens for @entity263 . [Table: see text].

title: Three-month change in PSA as a surrogate endpoint for mortality in advanced XXXX ( @entity263 ): Data from Southwest Oncology Group Study S9916.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity12749 :: ('MESH:D004961', 'Chemical') :: ['estramustine']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

answer: @entity263 :: (MESH:D011471,Disease) :: ['hormone-refractory prostate cancer']


abstract: PURPOSE: To determine long-term survival and potential cure with salvage chemotherapy with @entity1311 plus @entity136 after progression after both @entity900 combination chemotherapy and subsequent high-dose chemotherapy with tandem transplantation. @entity1 AND METHODS: One hundred eighty-four @entity1 received salvage high-dose chemotherapy at Indiana University (Indianapolis, IN) from February 1996 to December 2004. After further evidence of progressive disease, 32 @entity1 were subsequently treated with @entity1311 100 mg/n2 over 1 hour plus @entity136 1,000 mg/m2 over 30 minutes, days 1, 8, and 15 every 4 weeks for a maximum of six courses. This is a retrospective review of this @entity1 population. @entity1 were evaluated for response, duration of response, and survival. @entity1 were ineligible if they received prior @entity1311 or @entity136 . RESULTS: Ten (31%) of 32 @entity1 achieved objective response, including four partial remissions (2- to 6-month duration) and six complete responses (CRs). Four of these six CRs (12.5% of total @entity1 population) are continuously disease free (NED) with @entity1311 plus @entity136 alone (no postchemotherapy surgery) at more than 20, 40, 44, and 57 months from start of @entity1311 plus @entity136 , respectively. One additional CR is currently NED more than 63 months after @entity1311 plus @entity136 with two subsequent resections of @entity189 . CONCLUSION: Long-term disease-free survival is possible with @entity1311 plus @entity136 in this @entity1 population that progressed after high-dose chemotherapy, and had not received prior @entity1311 or @entity136 .

title: Phase II study of @entity1311 plus XXXX salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']


abstract: @entity1 admitted to medical intensive care unit (MICU) are at increased risk for @entity1211 ( @entity1211 ); and prophylaxis is recommended. However, the actual range and frequency of @entity1211 prophylaxis administered to MICU @entity1 are not well defined. @entity1 over 40 yr of age and expected MICU stay of more than 48 hr were eligible for this observational cohort study of 23 MICUs in Korea. @entity1 already on anticoagulation therapy or those requiring anticoagulation for reasons other than @entity1211 were excluded. Among 830 @entity1 , @entity1211 prophylaxis was given to 560 (67.5%) @entity1 . Among 560 @entity1 , 323 (38.9%) received pharmacoprophylaxis, 318 (38.4%) received mechanical prophylaxis and 81 (9.8%) received both forms of prophylaxis. About 74% of @entity1 in the pharmacoprophylaxis group received low molecular weight heparin and 53% of the @entity1 in the mechanical prophylaxis group used intermittent pneumatic compression. Most of the @entity1 (90%) had more than one risk factor for @entity1211 and the most common risk factor was old age, followed by heart and @entity1576 . In this observational cohort study of 23 MICUs in Korea, 67.5% of @entity1 received thromboprophylaxis. Further studies are needed to clarify the role and efficacy of @entity1211 prophylaxis in Korean critically ill @entity1 .

title: Prevention of XXXX in medical intensive care unit: a multicenter observational study in Korea.

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']


abstract: BACKGROUND: Reconstruction of larger @entity3066 may pose a dilemma for surgeons, since flaps used in reconstruction may be difficult to design, be unreliable, require extensive dissection, and result in neck scarring. Consequently, the authors wish to simplify and expand an overlooked flap, the @entity717 flap, which moves tissue in both a medial and upward direction. METHODS: Twenty @entity1 with @entity3066 were treated by the @entity717 flap. In this flap design, the angle designed below the ear was closed primarily and the neck tissue previously there was rotated upward and forward to lie in front of the ear. The portion of the flap that was in front of the ear was transposed to the lower lid/cheek area. This flap was modified in several @entity1 by elevation in the deep plane and first-stage tissue expansion. RESULTS: In all cases, good coverage was provided for medial cheek and lower @entity3066 with minimal scarring on the neck. There were no flap losses of any kind. There were no major complications, and all minor incidences were treated by minimal procedures without long-term sequelae. CONCLUSION: The modified @entity717 flap is a useful tool for @entity3066 .

title: Cheek and eyelid reconstruction: the resurrection of the XXXX flap.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['angle rotation']

entities_list: @entity3066 :: ('MESH:D005141', 'Disease') :: ['eyelid defects', 'cheek and eyelid defects']

answer: @entity717 :: (MESH:D009069,Disease) :: ['angle rotation']


abstract: UNASSIGNED: 5118 Background: Cervical @entity5 is the most common tunor among mexican female population. The majority of cases are seen in advanced stages. 40% of all the @entity1 will have recurrent disease and the 5 years survival of these @entity1 is of 20 to 30%. @entity136 and @entity2600 are active as single agents The aim of this trial was to prove the combination with @entity136 plus @entity2600 in @entity1 with recurrent @entity5 ,. @entity1 AND METHODS: 10 @entity1 were treated with the combination of @entity136 plus @entity2600 until disease progresi  n or limited @entity137 . (25-79); All @entity1 had histologically proven disease,; and all @entity1 had clinically measurable disease by CT scan. TREATMENT: @entity136 1000 mg/m2, @entity2600 100 mg/m2 days both day1 and 8, repeated q 21 days as blood count permited. RESULTS: We included 10 pt feb 03 to oct 03, median age was 50.5 years and all 10 had @entity5 and recurrent disease, pelvic in 7, metastatic in 1 and both in 2, initial treatment was radiotherapy in 8 and, in 2 @entity1 concurrent with @entity136 as radiosensitizer; GI was administered as first line therapy in 8 and as a second line in 2, @entity137 G3,4: we administered 37 courses and we had @entity417 in 9/37 (24%), @entity1210 in 1/37 (2.7%); @entity882 2/37 (5.4%), Non @entity1503 : alopecia G3,4 in 2 pt, one @entity1 with diarrea G4 who died. OR 3/10 (33%) CR was 2/10 (22%), @entity6972 (11%) and PD 6/10 (66%). the duration response in three pt has been 6, 6 and 4 mo, Median follow up was 5mo (range 3-9), MOS was 4.85 months. Actually we have one @entity1 alive without evidence disease and two alive with tumoral activity. Conclusi  n: @entity136 plus @entity2600 is an active and well tolareted scheme (R0 33%) in a very difficult group of @entity1 with recurrent @entity5 , we got responses in the three pt with metastasic disease one of them CR, except for the @entity344 in one @entity1 . No significant financial relationships to disclose.

title: @entity136 plus @entity2600 (GI) in recurrent XXXX : A pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['Irinotecan', 'irinotecan']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'epidermoid tumors', 'cervical cancer']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological toxicity']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['Leucopenia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: OBJECTIVE: To establish the prognostic importance of different @entity1 and @entity5 characteristics in cryotherapy for liver @entity3 from @entity14 . SUMMARY BACKGROUND DATA: Hepatic cryotherapy has been used as a treatment of nonresectable liver @entity3 from @entity14 in almost 1000 @entity1 worldwide, and its safety and efficacy are well established. However, @entity5 eventually recurs in most @entity1 and they die of their disease. The knowledge of prognostic factors would allow the selection of @entity1 who are more likely to benefit from this treatment and @entity1 who may need additional treatment. METHODS: Between April 1990 and May 1997, 195 @entity1 were treated with hepatic cryotherapy. Out of this group, the authors identified 116 @entity1 with @entity14 who received cryotherapy for ablation of liver @entity3 . Survival was estimated with the Kaplan-Meier method, using the log-rank test for univariate analysis for significance of possible prognostic factors. For multivariate analysis, a Cox regression was used. RESULTS: One @entity1 (0.9%) died of postoperative @entity583 . The total perioperative morbidity rate was 27.6%. Median survival and the 5-year survival rate were 26 months and 13.4%. The following factors were identified as independently associated with a favorable outcome: low presurgical serum level of @entity787 ( @entity787 ), small (< or =3 cm) diameter of cryoablated @entity3 , absence of untreated extrahepatic disease at laparotomy, absence of nodal involvement at primary resection, complete cryotreatment, synchronous development of liver @entity3 , and good or moderate differentiation of the @entity5 . Although univariate analysis suggested a favorable prognosis in @entity1 who did not receive blood transfusion during surgery and @entity1 younger than 51 years, this was not confirmed in multivariate analysis. In addition, normalization of the serum @entity787 level after treatment was an important prognostic marker in the subgroup of @entity1 with elevated serum @entity787 levels before surgery. CONCLUSIONS: Hepatic cryotherapy is a safe and effective treatment option for @entity1 with nonresectable liver @entity3 from @entity14 , with promising results regarding survival. The prognostic factors established in this series may allow better @entity1 selection to improve the outcome in suitable @entity1 .

title: Prognostic factors after cryotherapy for hepatic XXXX from @entity14 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor']

entities_list: @entity787 :: ('1084', 'Gene') :: ['CEA', 'carcinoembryonic antigen']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: BACKGROUND: Studies of fertility in @entity1 treated for @entity5 have mainly addressed serum follicle-stimulating hormone levels and sperm parameters. We assessed post-treatment paternity among long-term survivors of @entity5 . METHODS: @entity1 (n = 1814) who had been treated for unilateral @entity5 in Norway during 1980 through 1994 were invited to participate in a national multi-center follow-up survey in 1998 through 2002. The @entity1 were allocated to five groups according to the treatment received after orchiectomy, including treatment at relapse (surveillance, retroperitoneal lymph node dissection, radiotherapy, low-dose chemotherapy [i.e., < or = 850 mg @entity900 ], and high-dose chemotherapy [i.e., > 850 mg @entity900 ]). Cox proportional hazards analysis was used to assess predictive factors for post-treatment paternity. Statistical tests were two-sided. RESULTS: A total of 1433 @entity1 were assessable, of whom 827 were fathers at diagnosis. Post-treatment conception was attempted by 554 @entity1 , among whom the overall 15-year actuarial post-treatment paternity rate was 71% (95% confidence interval [CI] = 66% to 75%) without the use of cryopreserved semen. This rate ranged from 48% (95% CI = 30% to 69%) in the high-dose chemotherapy group to 92% (95% CI = 78% to 98%) in the surveillance group (P < .001). The median actuarial time from diagnosis to the birth of the first @entity1 after treatment was 6.6 years overall but varied according to treatment. Assisted reproductive technologies were used by 22% of the couples who attempted conception after treatment. @entity2133 , treatment group, pretreatment fatherhood, and marital status were statistically significant independent predictors for post-treatment fatherhood, with @entity2133 as the most important negative factor. CONCLUSIONS: Although the overall paternity rate after treatment for @entity5 was high, the ability to conceive and the time to conception reflected the intensity of treatment. These data may help inform @entity1 about their future ability to father biological @entity1 .

title: Paternity following treatment for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children', 'patients', 'Men', 'child', 'men']

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['Dry ejaculation', 'dry ejaculation']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['testicular cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['testicular cancer']


abstract: BACKGROUND: Bacterial Artificial Chromosomes (BACs) have been widely used as transgenes in vertebrate model systems such as @entity19 and @entity3392 , for a variety of studies. BAC transgenesis has been a powerful tool to study the function of the genome, and gene regulation by distal cis-regulatory elements. Recently, BAC transgenesis in both @entity19 and @entity3392 was further facilitated by development of the transposon-mediated method using the Tol2 element. Tol2 ends, in the inverted orientation and flanking a 1 kb spacer DNA (iTol2), were introduced into the BAC DNA within the bacterial host using recombination of homologous sequences. Here we describe experiments designed to determine if a simpler and more flexible system could modify BACs so that they would be suitable for transgenesis into @entity3392 or @entity19 embryos using the Tol2 transposase. RESULTS: A new technique was developed to introduce recognition sequences for the Tol2 transposase into BACs in @entity526 using the Tn10 transposon vector system. We constructed pTnloxP-iTol2kan and pTnlox511-iTol2kan to introduce the loxP or lox511 site and iTol2 cassette, containing the Tol2 cis-sequences in the inverted orientation, into BACs that have loxP and lox511 sites flanking genomic DNA inserts by Tn10-mediated transposition. The procedure enables rapid generation of a large collection of BACs ready for transgenesis with the iTol2 cassette at the new end of a progressively truncated genomic insert via @entity60290 -Cre recombination. The iTol2 ends are efficiently recognized by the Tol2 transposase, and the BACs readily integrate into @entity3392 chromosomes. CONCLUSION: The new technology described here can rapidly introduce iTol2 ends at a BAC end of choice, and simultaneously generate a large collection of BACs with progressive deletions of the genomic DNA from that end in a single experiment. This procedure should be applicable to a wider variety of BACs containing @entity60290 sites flanking the genomic DNA insert, including those with sequence repeats. The libraries of iTol2 inserted BACs with truncations from an end should facilitate studies on the impact of distal cis-regulatory sequences on gene function, as well as standard BAC transgenesis with precisely trimmed genes in @entity3392 or @entity19 embryos using Tol2 transposition.

title: Generating libraries of iTol2-end insertions at BAC ends using loxP and XXXX 511 Tn10 transposons.

answer: @entity60290 :: (404621(Tax:7955),Gene) :: ['lox']


abstract: This study aimed to identify the predictors of outcome in 102 @entity1 following their first admission with acute @entity662 . Outcome was measured at three months by interview and at five years by questionnaire. @entity662 , change in physical activity, return to work, smoking, @entity146 , and mortality were assessed. The principal predictors of @entity662 and smoking were previous @entity146 and a diagnosis of non-specific @entity662 ; a previous history of @entity146 was associated with a five-fold increase in the risk of continued @entity662 at five-year follow-up (95% CI = 1.1-25.0). @entity146 at five years was predicted by @entity146 at admission (adjusted odds ratio (adj OR) = 3.2; 95% CI 1.0-11.0) and non-specific @entity662 (adj OR = 7.5; 95% CI = 1.7-32.1). Mortality at five-year follow-up was independently associated with older age (adj OR = 1.1; 95% CI = 1.01-1.2), an elevated Norris score (adj OR = 1.41; 95% CI = 1.01-1.96) and a previous history of @entity146 (adj OR = 5.06; 95% CI = 1.13-22.0). These findings suggest that prediction of outcome, irrespective of underlying diagnosis, requires careful assessment of previous or current @entity146 in @entity1 admitted with @entity662 . Early intervention with psychological treatment for @entity1 with non-specific @entity662 should be considered; this may also involve help to reduce smoking. The study provides further evidence that mortality following @entity583 is closely linked to @entity146 , but suggests that prior @entity146 may be more important than 'post- @entity1188 ' @entity308 . A larger study is needed to confirm these results.

title: Predictors of mortality and morbidity following admission with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['Chest pain', 'chest pain']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Psychiatric disorder', 'psychiatric symptoms', 'psychiatric disorder']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction']

answer: @entity662 :: (MESH:D002637,Disease) :: ['chest pain']


abstract: @entity4153 of the breast is exceedingly rare, with fewer than 25 reported cases. The case presented herein is that of a 61-year-old @entity1 with a 2.5-cm mass of the left breast. She underwent mastectomy with axillary node dissection. Histologic examination revealed sheets and nests of small, hyperchromatic, malignant cells with indistinct nucleoli and scant cytoplasm. High-grade solid and comedo @entity513 in situ also was present. Two of 5 axillary lymph nodes contained metastatic disease. Immunohistochemical analysis demonstrated weak immunoreactivity for cytokeratin, @entity3508 , and @entity588 . This histologic and immunohistochemical profile was consistent with that of a primary @entity4153 . Interestingly, this @entity5 lacked immunoreactivity for @entity5962 . @entity5962 expression has been documented in all 11 (100%) of 11 previously reported cases of primary small cell @entity0 , suggesting that this @entity5 is a form of @entity513 . To our knowledge, this is the first reported case of @entity5962 -negative small cell @entity0 , which raises the question of a possible lobular histogenesis in some of these @entity5 .

title: @entity5962 -negative primary small cell XXXX . Report of a case and review of the literature.

entities_list: @entity4153 :: ('MESH:D018288', 'Disease') :: ['small cell carcinoma', 'Primary small cell carcinoma']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['carcinoma of the breast']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasms', 'neoplasm']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['ductal carcinoma']

entities_list: @entity3508 :: ('2026', 'Gene') :: ['neuron-specific enolase']

answer: @entity0 :: (MESH:D001943,Disease) :: ['carcinoma of the breast']


abstract: PURPOSE: To evaluate the feasibility, safety, and technical efficacy of image-guided radiofrequency ablation (RFA) for the treatment of small peripheral @entity703 and to report our early results with this treatment modality. METHODS: Twenty-two RFA sessions for 18 @entity5 were performed in 11 @entity1 with @entity703 . Indications included coexistent morbidity, high surgical or anesthetic risk, solitary kidney, and hereditary predisposition to @entity1358 . Ten @entity1 had CT-guided percutaneous RFA performed on an outpatient basis. One @entity1 had open intraoperative ultrasound-guided RFA. Technical success was defined as elimination of areas that enhanced at imaging within the entire @entity5 . With the exception of one @entity1 with @entity177 who required @entity2287 -enhanced MRI, the remaining @entity1 underwent contrast-enhanced CT for post-treatment follow-up assessment. Follow-up was performed after 2-4 weeks and then at 3, 6, 12 months, and every 12 months thereafter. RESULTS: Fourteen (78%) of 18 @entity5 were successfully ablated with one session. Three of the remaining four @entity5 required two sessions for successful ablation. One @entity5 will require a third session for areas of persistent enhancement. Mean @entity1 age was 72.82 +/- 10.43 years. Mean @entity5 size was 1.95 +/- 0.79 cm. Mean follow-up time was 10.91 months. All procedures were performed without any major complications. CONCLUSIONS: Our early experience with percutaneous image-guided radiofrequency ablation demonstrates it to be a feasible, safe, noninvasive, and effective treatment of small peripheral @entity703 .

title: @entity703 : technical success and early clinical experience with radiofrequency ablation of 18 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumors']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: UNASSIGNED: Background: For @entity1 awaiting liver transplantation, we aimed to determine the prevalence and predictors of insufficient @entity1131 as well as to determine whether very low @entity1131 was an independent predictor of @entity3147 and mortality. Materials and Methods: Adults with @entity82 who were activated on our local liver transplant waiting list between January 2000 and October 2009 were included. Estimated @entity1131 was derived from dietary records. @entity1 with incomplete dietary records were excluded. Multivariable logistic regression and competing risk analysis were used. Results: Of 742 potential @entity1 , 112 were excluded due to insufficient data, leaving 630 @entity1 for evaluation. Mean @entity1131 was 1.0    0.36 g/kg/d and only 24% of @entity1 met the expert consensus recommended threshold of > 1.2 g/kg of protein per day. Very low @entity1131 (< 0.8 g/kg/d) was associated with worse @entity409 severity (as measured by @entity1 -Pugh or MELD). Protein intake below 0.8 g/kg/d was an independent predictor both of @entity3147 as measured by the subjective global assessment (adjusted odds ratio [95% confidence interval (CI)]: 2.0 [1.3-3.0]) and of transplant waiting list mortality (adjusted hazard ratio [95% CI]: 1.8 [1.2-2.7]). Conclusion: In this large cohort of liver transplant waitlisted @entity1 , very low @entity1131 was prevalent and independently associated with @entity3147 and mortality. Unlike many other prognostic factors, @entity1131 is potentially modifiable. Prospective studies are warranted to evaluate the effect of targeted protein repletion on clinically relevant outcomes such as muscle mass, muscle function, immune function, and mortality.

title: Insufficient Protein Intake Is Associated With Increased Mortality in 630 @entity1 With @entity82 Awaiting XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'Patients', 'patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity1131 :: ('MESH:D011488', 'Disease') :: ['protein intake']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

answer: @entity409 :: (MESH:D008107,Disease) :: ['Liver Transplantation']